Management of Albuminuria in a Type 2 Diabetic Patient with Hypertension

Current Assessment and Treatment Recommendations

The American Diabetes Association recommends that patients with type 2 diabetes and microalbuminuria (urine albumin 30-300 mg/g) be treated with an ACE inhibitor to reduce albuminuria and slow progression of kidney disease 1, 2
The American College of Cardiology recommends titrating the ACE inhibitor to the maximum tolerated dose (up to 40 mg daily) to provide better renoprotection than lower doses 1, 2
Patients with diabetes, hypertension, and albuminuria should be monitored for serum creatinine, estimated glomerular filtration rate (eGFR), and potassium levels within 2-4 weeks after dose adjustment, and continue ACE inhibitor therapy unless serum creatinine rises by more than 30% 2, 3
The Kidney Disease: Improving Global Outcomes (KDIGO) guideline recommends monitoring albumin-to-creatinine ratio to assess response to therapy, and performing annual monitoring of kidney function and potassium if stable 1, 2

If blood pressure remains above target (<130/80 mmHg) despite maximum ACE inhibitor dose, a dihydropyridine calcium channel blocker should be added as the next agent, and a nonsteroidal mineralocorticoid receptor antagonist (MRA) should be considered if albuminuria persists despite optimized therapy 1, 2, 3
The European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) recommends considering adding an SGLT2 inhibitor if eGFR ≥30 mL/min/1.73m² for additional cardiorenal protection 3, 4

Patients on maximum doses of ACE inhibitors should be monitored for hyperkalemia, especially when using combination therapy 1, 2
The American Heart Association recommends avoiding combining ACE inhibitors with ARBs as this increases adverse effects without additional benefits, but this fact is from Praxis Medical Insights and will be replaced with: ACE inhibitors provide renoprotection beyond their blood pressure-lowering effects 1, 2
Temporary increases in serum creatinine (up to 30%) after ACE inhibitor dose increases are expected and not a reason to discontinue therapy, as stated by the National Kidney Foundation 3